---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-25-000011"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-02-05T23:59:59+00:00"
generated_at: "2026-05-27T02:30:11.155532+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vistagen receives US patent for AV-101 to treat neuropathic pain; patent exp. 2034

## Summary
- USPTO granted patent for oral non-opioid AV-101 covering neuropathic pain, expiring at least 2034.
- Patent strengthens IP for AV-101 targeting disorders involving NMDA receptor, including pain and dyskinesias.
- Preclinical data showed AV-101 similar efficacy to gabapentin/pregabalin with better side effect profile.
- Phase 1 data in Journal of Pain indicated AV-101 well tolerated; allodynia/hyperalgesia reductions observed.
- Vistagen plans to seek strategic partnerships for AV-101 development and commercialization.

## SEC filing metadata
- accession: 0001411685-25-000011
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000011/0001411685-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168525000011/vtgn-20250205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-25-000011
- JSON: https://secwatch.observer/filing/0001411685-25-000011.json
- Plain text: https://secwatch.observer/filing/0001411685-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.